International Clinical Trial: A single-arm, phase II clinical study of orelabrutinib combined with low-dose radiotherapy in the treatment of newly diagnosed early-stage marginal zone lymphoma (MZL)

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133509) titled 'A single-arm, phase II clinical study of orelabrutinib combined with low-dose radiotherapy in the treatment of newly diagnosed early-stage marginal zone lymphoma (MZL)' on Sept. 28.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Xiamen University

Condition: Marginal zone lymphomas

Intervention: Combination of low-dose radiotherapy and obubitinib:After treatment with 6 cycles of obubitinib plus 4 Gy of radiotherapy (28 D/cycle) , patients whose efficacy was assessed as > = PR continued to receive 6 cycles of obubitinib (28 D/cycle) and patients wit...